IL126411A0 - Alpha1-Adrenergic receptor antagonists - Google Patents

Alpha1-Adrenergic receptor antagonists

Info

Publication number
IL126411A0
IL126411A0 IL12641197A IL12641197A IL126411A0 IL 126411 A0 IL126411 A0 IL 126411A0 IL 12641197 A IL12641197 A IL 12641197A IL 12641197 A IL12641197 A IL 12641197A IL 126411 A0 IL126411 A0 IL 126411A0
Authority
IL
Israel
Prior art keywords
alpha1
receptor antagonists
adrenergic receptor
derivatives
adrenoreceptor
Prior art date
Application number
IL12641197A
Other languages
English (en)
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of IL126411A0 publication Critical patent/IL126411A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
IL12641197A 1996-04-05 1997-04-04 Alpha1-Adrenergic receptor antagonists IL126411A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62827696A 1996-04-05 1996-04-05
PCT/FR1997/000615 WO1997037983A1 (fr) 1996-04-05 1997-04-04 ANTAGONISTES DU RECEPTEUR α1-ADRENERGIQUE

Publications (1)

Publication Number Publication Date
IL126411A0 true IL126411A0 (en) 1999-05-09

Family

ID=24518205

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12641197A IL126411A0 (en) 1996-04-05 1997-04-04 Alpha1-Adrenergic receptor antagonists

Country Status (15)

Country Link
US (1) US6300499B1 (cs)
EP (1) EP0891344B1 (cs)
JP (1) JP3845452B2 (cs)
AT (1) ATE229946T1 (cs)
AU (1) AU2393997A (cs)
CZ (1) CZ315098A3 (cs)
DE (1) DE69717978T2 (cs)
DK (1) DK0891344T3 (cs)
ES (1) ES2188936T3 (cs)
HU (1) HUP9901680A3 (cs)
IL (1) IL126411A0 (cs)
NO (1) NO984631L (cs)
PL (1) PL329190A1 (cs)
RU (1) RU2179554C2 (cs)
WO (1) WO1997037983A1 (cs)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5661163A (en) * 1995-06-07 1997-08-26 Merck & Co., Inc. Alpha-1a adrenergic receptor antagonists
GB9819860D0 (en) 1998-09-12 1998-11-04 Zeneca Ltd Chemical compounds
JP2005532282A (ja) * 2002-04-08 2005-10-27 ランバクシー ラボラトリーズ リミテッド 有用な泌尿ー選択性α１Ａアドレノレセプターブロッカーとしてのカルボキシイミド体
EP1519726B1 (de) * 2002-07-04 2007-02-21 Schwarz Pharma Ag Heteroarencarboxamide zur verwendung als dopamin-d3 liganden zur behandlung von zns-erkrankungen
DE10251170A1 (de) * 2002-10-31 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
WO2006021344A1 (en) * 2004-08-27 2006-03-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with alpha-1a adrenergic receptor (adra1a)
WO2013038427A1 (en) * 2011-09-12 2013-03-21 Council Of Scientific & Industrial Research ARYLATED β-DICARBOIMYL COMPOUNDS AND PROCESS FOR THE PREPARATION THEREOF
CN103304486A (zh) * 2013-06-25 2013-09-18 南方医科大学 6-（4-芳基哌嗪-1-基）哒嗪-3（2h）-酮及其应用
CN103288745A (zh) * 2013-06-25 2013-09-11 南方医科大学 一种2,6-二取代哒嗪酮类化合物及其应用
JPWO2015029447A1 (ja) * 2013-08-30 2017-03-02 興和株式会社 光学活性カルビノール化合物の製造方法
CN115124415A (zh) * 2022-06-20 2022-09-30 西咸新区行易先进材料科技有限公司 一种合成阿卓乳酸的催化反应方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2833770A (en) * 1958-05-06 Chj-chj
US2722529A (en) * 1955-11-01 Amides of certain l-amevoalkyl-x-phenyl
NL8005133A (nl) * 1980-09-12 1982-04-01 Duphar Int Res Fenylpiperazinederivaten met antiagressieve werking.
CA1340113C (en) * 1988-05-24 1998-11-03 Magid A. Abou-Gharbia Aryl-and heteroaryl piperazinyl carboxamides having central nervous system activity
PT93824B (pt) * 1989-04-22 1996-09-30 Wyeth John & Brother Ltd Processo para a preparacao de derivados de piperazina
FR2655988B1 (fr) 1989-12-20 1994-05-20 Adir Cie Nouveaux derives de la napht-1-yl piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DE4121276C2 (de) 1991-06-27 1994-02-17 Metallgesellschaft Ag Verfahren zur Herstellung sulfathaltiger, basischer Polyaluminiumchlorid-Lösungen
GB9200293D0 (en) 1992-01-08 1992-02-26 Wyeth John & Brother Ltd Piperazine derivatives
SE9201138D0 (sv) * 1992-04-09 1992-04-09 Astra Ab Novel phthalimidoalkylpiperazines
US5284990A (en) 1992-07-16 1994-02-08 Stratco, Inc. Method for converting a hydrogen fluoride alkylation unit to a sulfuric acid alkylation unit
US5349844A (en) 1992-09-11 1994-09-27 Trc Companies, Inc. System and method for resonant filter mass monitoring
SE9300295D0 (sv) 1993-01-28 1993-01-28 Benny Carlstroem Foerfarande och anordning foer bindning av tandlagningsmaterial
ZA944513B (en) * 1993-06-23 1996-01-16 Cambridge Neuroscience Inc Sigma receptor ligands
US5414585A (en) 1993-07-19 1995-05-09 Quantum Corp. Rotating tape edge guide
IT1266582B1 (it) * 1993-07-30 1997-01-09 Recordati Chem Pharm Derivati (di)azacicloesanici e diazacicloeptanici
US5696123A (en) * 1994-09-17 1997-12-09 Boehringer Ingelheim Kg Neurokinin antagonists

Also Published As

Publication number Publication date
US6300499B1 (en) 2001-10-09
DE69717978T2 (de) 2003-10-02
ES2188936T3 (es) 2003-07-01
WO1997037983A1 (fr) 1997-10-16
PL329190A1 (en) 1999-03-15
HUP9901680A2 (hu) 1999-09-28
EP0891344B1 (fr) 2002-12-18
AU2393997A (en) 1997-10-29
CZ315098A3 (cs) 1999-04-14
HUP9901680A3 (en) 2000-12-28
JP2000508310A (ja) 2000-07-04
ATE229946T1 (de) 2003-01-15
NO984631D0 (no) 1998-10-02
NO984631L (no) 1998-12-02
JP3845452B2 (ja) 2006-11-15
DE69717978D1 (de) 2003-01-30
EP0891344A1 (fr) 1999-01-20
RU2179554C2 (ru) 2002-02-20
DK0891344T3 (da) 2003-04-07

Similar Documents

Publication Publication Date Title
IL101243A0 (en) Pharmaceutical compositions for treatment of benign prostatic hyperplasia
EA200000220A1 (ru) Сочетание ингибитора тирозинкиназы и химической стерилизации для лечения рака предстательной железы
MY106484A (en) Combination therapy for phophylaxis and/or treatment of benign prostatic hyperplasia.
MY131298A (en) 5-heteroyl indole derivatives
IL107581A0 (en) Use of alpha-ic specific compounds to treat benign prostatic hyperplasia
IL126411A0 (en) Alpha1-Adrenergic receptor antagonists
AU1316000A (en) Compositions and methods for treating benign prostatic hyperplasia using tocotrienols
ZA986673B (en) Use of a combination of an inhibitor of converting enzyme and a diuretic for treating microcirculatory disorders
AU5861799A (en) Use of acetylcholinesterase inhibitors for the preparation of pharmaceutical compositions for the treatment of functional and/or organic pain syndromes
ID19470A (id) Komposisi bahan pembangkit gas
AU2443184A (en) Benzazocinones and benzazoninones
HUP9902026A3 (en) Use of bicyclic 4-aralkylaminopyrimidine derivatives for producing pharmaceutical compositions having tyrosine kinase inhibitor effect, novel bicicyclic 4-aralkylaminopirimidine derivatives and pharmaceutical compositions containing them
ZA952763B (en) Use of alpha-1C specific compounds to treat benign prostatic hyperplasia
PL318186A1 (en) Gas generating composition, method of obtaining such composition and premix of components for obtaining such composition
BG103553A (en) Benzopyranopyrol and benzopyranopyridine alpha-1 adrenergic compounds
AU9128998A (en) Composition and method for the treatment of benign prostatic hyperplasia and prostatitis
HU9601498D0 (en) Use of dimeticone for treating constipation
EP0633781A4 (en) COMPOSITIONS AND METHODS FOR TREATING BENIGN PROSTATIC HYPERTROPHY.
AU5457694A (en) Methods and compositions of (-) doxazosin for the treatment of benign prostatic hyperplasia and atherosclerosis
HUP9901139A3 (en) Use of melatonin agonists for producing pharmaceutical compositions suitable for treating benign prostatic hyperplasia
IT1283124B1 (it) Forme e composizioni farmaceutiche per il trattamento dell'ipertrofia prostatica benigna
TW340108B (en) 1,1-difluoro-1,4-dichlorobutane and process for its preparation
NZ333506A (en) Methanesulphonate salt of an arylpiperazine derived from tryptamine and its solvates for pharmaceutical use
HUT67527A (en) Arylalkoxyphenoxy-imidazoline derivatives and pharmaceutical compositions containing them
AU6374798A (en) Methods and compositions of (+) doxazosin for the treatment of hypertension and benign prostatic hyperplasia